VEGF-165b protein therapy (University of Bristol)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameVEGF-165b protein therapy (University of Bristol)
Drug Alias NameVEGF-A165bangiogenesis inhibitor (Bristol University)
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionVascular endothelial growth factor receptor antagonists
TargetsVascular endothelial growth factor receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Bristol
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Bristol
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A